PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of jcancEditorial BoardAuthor infoSubmit a manuscriptJournal of Cancer website
 
J Cancer. 2017; 8(15): 2915–2923.
Published online 2017 August 25. doi:  10.7150/jca.20314
PMCID: PMC5604442

Immune Cell Population in Ovarian Tumor Microenvironment

Abstract

Ovarian cancer, the third most common with highest mortality rates gynecological malignancy among women in China, is characterized by a unique tumor immune microenvironment. Immune-cell population infiltrated into the tumor tissue among patients with ovarian cancer are associated positively or negatively with antitumor activity. The imbalance between immune activation and immune suppression can result in oncogenesis and cancer progression. Therefore, intense investigation of the immunologic mechanism of ovarian cancer is urgently needed, and a comprehensive understanding of the network in which immune cells interact with the microenvironment, tumor cells and each other will greatly promote the development of more effective immunotherapies for ovarian cancer. In this review, we will focus on the main immune-cell population in ovarian tumor microenvironment, discuss their role in tumor progression and try to give the readers a new perspective in finding more promising therapeutic targets for cancers.

Keywords: ovarian cancer, tumor microenvironment, immune cell population.

Introduction

Although considerable improvements in surgery, conventional chemotherapy, and even novel therapeutic strategies for ovarian cancer have been achieved in the past few years, ovarian cancer remains the cause of the highest mortality rates of tumors in women. This malignant disease is often diagnosed late, progresses rapidly, and recurs prevalently and is thus associated with adverse clinical outcomes. It has been verified that ovarian cancer, like many other solid tumors, is immunogenic, so immune cells may emerge as key players in tumor pathology and potential therapeutic targets. The accumulation of tumor-infiltrating lymphocytes (TILs) infiltrated in the tumor microenvironment (TME) can be involved in antitumor activity, while simultaneously, a plethora of immunosuppressive cells, including tumor-associated macrophages (TAMs), regulatory T cells (Tregs), and myeloid-derived suppressor cells (MDSCs) as well as Tumor-associated dendritic cells (tDCs) in ovarian cancer tissue, serve as accomplices that orchestrate a highly complex immunosuppressive network to impede successful antitumor immunity and assist tumor cells in evading immune attack. Obviously, in addition to immune cell population, ovarian cancer cells also lead to the immunosuppressive microenvironment in various ways that allow evasion of cancer suppression. Given this scenario, the need for accurate academic research into infiltrated immune-cell networks and the ovarian tumor microenvironment is urgent. In this review, we discuss the characteristics of immune cells infiltrated in the TME and their roles in ovarian cancer.

Tumor-associated macrophages (TAMs)

TAMs, a preponderant infiltrating subset in human ovarian cancer 1, established an immunosuppressive microenvironment that allows tumors to evade immune surveillance and promotes tumor growth, invasion, and metastasis. The common view was that TAMs are skewed to the M2-polarized phenotype 2. However, genome-wide expression profiling of TAMs in patients with high-grade serous ovarian adenocarcinoma demonstrated that TAMs display a mixed-polarization phenotype. Not only typical M2 markers, including IL-10 and CD163, but also some M1 markers such as CD86 and TNF-α are upregulated 3.

In addition to heterogeneity, another hallmark of macrophages is high plasticity. Circulating monocytes can be recruited and induced differentiation into TAMs by ovarian cancer cells in the TME. CCL2, also known as monocyte chemotactic protein-1 (MCP-1), is overexpressed in ovarian cancer cell lines as well as primary tumor cells 4, and its receptor CCR2 is detected in TAMs derived from ovarian cancer patients 5. Ovarian cancer may retain recruited circulating monocytes to tumor tissue though CCL2-CCR2 pathway. Tissue-resident macrophages are found also a substantial source for the TAMs 6. A surprising similarity between resident peritoneal macrophages and TAMs isolated from ovarian cancer ascites has been revealed recently. Both peritoneal macrophages and TAMs are highly expressed CD163 and CD206, as well as genes with essential functions in phagocytosis and antigen presentation 7.

The polarization of recruited monocytes strongly depends on the TME. In ovarian cancer patients, Colony stimulating factor-1(CSF-1) was found to be overexpressed and indicated a poor prognosis. CSF-1 is a critical cytokine that regulates the differentiation, growth, and function of macrophages and morphs macrophages into M2-polarized phenotype 8. CSF-1R (c-Fms) inhibition increase the proportion of M1 macrophages expressing CCR2, IL-12, and interferon-γ (IFN-γ) significantly, thus lower the immunosuppressive state of the TME and improve the outcome of ovarian cancer patients 9. Moreover, by enabling monocytes to consume CSF-1 in the high concentration of tumor-associated leukemia inhibitory factor (LIF) and IL-6 in ovarian cancer ascites can also promote the generation of TAMs 10. In addition to the soluble cytokines, mucins are also involved in the formation of TAMs. When co-cultured with ovarian cancer cells, macrophages unregulated the expression of M2-associated macrophage mannose receptor (MR, CD206) 11. MR was reported predominantly expressed in TAMs isolated from ovarian cancer patients. When engaged by tumor mucins (such as CA125 and TAG-72), MR activates TAMs toward an immune-suppressive profile: increasing IL-10 and decreasing IL-12 and CCL3 12. Mucin2 (MUC2) is expressed on ovarian cancer cells aberrantly and is an independent poor prognostic factor in ovarian cancer patients. The expression of MUC2 on tumor cells is inversely associated with M1/M2 ratio of TAMs and promotes cancer growth and metastasis through a TAMs-dependent pathway 13.

Epithelial ovarian cancer-derived exosomal MIR-222-3p have recently been reported to induce macrophages transformation to a TAMs-like phenotype. MIR-222-3p enriched in epithelial ovarian cancer-derived exosomes can upregulate the level of MIR-222-3p in macrophages, which in turns promote microphages differentiation to M2 phenotypes by decreases SOCS3 expression and activates SATA3 signaling. MIR-222-3p induced TAMs can enhance growth and metastasis of ovarian cancer cells 14. Hypoxia is also an important factor in promoting TAMs accumulation. Studies demonstrated that TAMs are often found in the hypoxic areas of tumor with high density. An article published in recent years revealed that increased 5-lipoxygenase (5-LOX) metabolites from ovarian cancer cells under hypoxic condition promote migration and invasion of TAMs by mediated the upregulation of matrix metalloproteinase-7 (MMP-7) through the p38 pathway. The release of TNF- α also enhanced in this progress. Tumor bearing mice model shows that blockade 5-LOX selectively and specifically can reduce the MMP-7 expression and the number of TAMs in tumor tissues 15. As mentioned above, naïve peritoneal macrophages can be induced into TAMs as well. A study found that a high increased TAMs in ovarian cancer mouse xenograft model expressed a homeobox gene HOXA9. HOXA9 expression was shown strongly associated with the TAMs accumulation in ovarian cancer patients 16.

After “re-educated”, macrophages mutinied and began to assist in tumor progression comprehensively. Compared to the cells separated from healthy donors, monocytes and macrophages derived from ovarian cancer patients increase in number, display a less differentiated phenotype, show deficient cytotoxicity and phagocytic abilities, and boost impaired antitumor activities 17. Both progression free survival and overall survival were indicated significantly reducing in ovarian cancer patients with high numbers of CD163+ cells 18. An animal experiment demonstrated that chemically depleting macrophages decreased tumor dissemination and ascites accumulation dramatically in ovarian cancer-bearing mice 19.

Expression of macrophage migration inhibitory factor (MIF) and extracellular matrix metalloproteinase inducer (EMMPRIN) in ovarian cancer cells upregulate MMP secretion by macrophages, and then overexpressed MMP promotes ovarian cancer invasion and angiogenesis 20. MIF blocking in ovarian tumor-bearing mice decreases macrophage infiltration in ascites as well as IL-6, IL-10 and TNF-α, thus increasing overall survival 21. Furthermore, downregulated MIF in ovarian cancer cells decreased the production of CCL2 and CCL22 in vitro 21. CCL22, upregulated and secreted by ovarian TAMs, can promote Tregs trafficking to the tumor 22. CCL18, an immunosuppressive chemokine expressed by TAMs, has been found in high levels in ovarian cancer patients. The increased level of CCL18 in ascites and serum of ovarian cancer patients promotes tumor migration 23 and metastasis 24 and is associated with worse survival rates. IFN-γ treatment is able to reduce the secretion of CCL18 and switch TAMs from immunosuppression to immunostimulatory 25. In the early stages of ovarian cancer transcoelomic metastasis, TAMs were found to promote spheroid formation and tumor growth in ID8-bearing mice model by endothelial growth factor (EGF) secretion. The EGF secreted by TAMs which located in the center of the spheroid upregulated the αMβ2 integrin on TAMs and intercellular cell adhesion molecule-1 (ICAM-1) on tumor cells to promote the connection between TAMs and tumor tissues. Moreover, EGFR on tumor cells was also activated by EGF, which in turn upregulated the VEGF/VEGFR signaling in tumor cells and ultimately led to the tumor growth and migration. Blocking the VEGF/VEGFR signaling or neutralizing ICAM-1 blunted spheroid and tumor progression in animal model 26.

Scavenger receptor-A (SR-A, CD204) expressed on TAMs, which is dependent on the presence of TNF-α, was demonstrated involved in promoting tumor cell invasion 11. SR-A defective macrophages reduce the invasiveness of ovarian cancer cells in vitro. Compared to the control group, tumor progression and metastasis are inhibited in SR-A (-/-) mice 27. In addition, TNFα-dependent activation of c-Jun N-terminal kinase (JNK) and transcription nuclear factor kappa B(NF-κB) signaling pathways was also involved in increasing the invasiveness of tumor cells when co-cultured with macrophages 20. Blocking NF-κB signaling pathways in ovarian TAMs decreases the level of M2-associated cytokines and increases M1-associated IL-12 and NOS, consequently preventing tumor cell invasion 28. The effect of TNF-α on a tumor depends on the dose and timing. Chronic, low-dose exposure promotes tumor progression, while a single high dose is tumor regressing. TNF-α upregulates the activity of ovarian cancer cells, alters the cellular morphology and enhances tumorigenesis and angiogenesis after binding with its receptors 29. The expression of TNF-α is closely correlated with the accumulation of IL-6 and CXCL12, which are involved in an autocrine cytokine network, the “TNF network” 30, which has been defined in human ovarian cancer recently. The “TNF network” plays a paracrine role in angiogenesis, myeloid cell infiltration and NOTCH signaling in both a mouse model and human ovarian cancer specimens 30, and inhibition of the “TNF network” in the mouse model confirmed this conclusion. An elevated level of IL-6 in ascites and serum of ovarian cancer is associated with the generation of TAMs 10 and the reduction of apoptotic signal sensitivity and angiogenesis 31, which promote cancer progression directly. CXCR4 is constitutively expressed in ovarian cancer, and CXCL12 has been found to be highly concentrated in ascites of ovarian cancer. The CXCR4-CXCL12 pathway participates in stimulation of invasion, recruitment of immunosuppressive cells and angiogenesis. Blockading the CXCR4-CXCL12 pathway increases the survival rate of tumor-bearing mice by decreasing Tregs and increasing the CD8/Treg ratio 32. A latest article reviewed that high levels of CXCL12 upregulated by TGF-β1 accumulated in the human peritoneal mesothelial cells (HPMCs), which serves as scaffolding for the premier step of peritoneal metastasis, of ovarian cancer patients enhance the crosstalk between tumor cells and HPMCs and promote peritoneal metastasis 33.

In addition, more than 70% of freshly isolated TAMs from ovarian cancer patients expressed B7-H4, a co-inhibitory molecule in the B7-CD28 family, the high concentrations of IL-10 and IL-6 are responsible for this 34. Accumulation of B7-H4-expressing macrophages in the TME impedes T-cell responses and correlates with more rapid tumor recurrence. Selectively blocking B7-H4 expressed on the surface of ovarian TAMs significantly increased T-cell proliferation 34. Furthermore, the intensity of B7-H4 on TAMs was positively associated with the cell numbers of Tregs 35.

Moreover, TAMs may be involved in pathological neovascularization. The functional crosstalk between macrophages and endothelial cells is an important topic in cancer and vascular biology. Co-culturing ovarian cancer cell lines with TAMs increases endothelial cell migration and tube formation, as well as the accumulation of pro-angiogenic cytokine IL-8 significantly 36. TAMs also have been reported to promote lymphangiogenesis in ovarian cancer. A study about a total of 108 ovarian tissue specimens found that TAMs could facilitate lymphangiogenesis by inducing lymphatic endothelial cell proliferation, migration and capillary-like tube formation. Even combining with high-mobility group box protein 1 (HMGB1) may augment this property 37.

Regulation T cells (Tregs)

Treg-mediated immunosuppression is also a major obstacle towards successful antitumor response. The high frequency of Tregs infiltration in the circulation or in the ovarian cancer tissues is correlated with increased mortality 22. Some investigators assessed the high expression of Foxp3 in ovarian cancer and found that it is an independent indicator of unfavorable clinical outcomes 38.

The ovarian tumor milieu favors the induction and differentiation of Tregs by a variety of pathways. CCR4/CCL22 and CCL17 signaling is known as the most predominant axis in selectively trafficking Tregs to tumors. It has been demonstrated that ovarian cancers and ascites cells highly express CCL22 in mRNA level compared to normal ovaries, and TAMs are the major sources of CCL22 22. A study of 104 ovarian cancer patients shows that the accumulation of Tregs in tumors mediated by CCL22 is associated with reduced survival and a high risk of patient death 22. CCL22 blockade significantly decreased Treg migration 22. In addition, CCR5/CCL5 were also involved in Tregs trafficking, and blockading these axes reduces infiltration of Tregs 39.

It has been shown that a strong Th17 response in early tumor stages has been replaced by a predominance of Tregs in late stages, confirming that tumor progression can sculpt Treg involvement in the local immune microenvironment 40. Indoleamine 2,3-dioxygenase (IDO), an enzyme that catalyzes tryptophan degradation, is expressed in many kinds of tumors, including ovarian cancer, and is associated with lower overall survival. The accumulation of IDO in tumors leads to induction of tryptophan catabolite kynurenine. Kynurenine then binds the aryl hydrocarbon receptor (AhR) on T cells, which shifts the Th17/Tregs balance in favor of Treg generation. Moreover, kynurenine can bind AhR on TAMs, further inducing the expression of IDO in a feedback loop. In addition, tumor-associated DCs infiltrated in ovarian cancer milieu also manipulate the transformation of Tregs. Dysfunctional DCs infiltrated in the tumor milieu contribute directly to the induction of IL-10-producing Tregs 41. Tumor-associated TGFβ-producing immature DCs can also promote Treg proliferation in a TGFβ-dependent manner selectively 42. Additionally, the action of TGFβ can convert Tregs from naïve T cells 43. CD8+ Tregs can be induced in ovarian cancer by plasmacytoid DCs 44. Human ovarian cancer and cancer-associated antigen-presenting cells express high levels of co-inhibitory members, PD-L1 45 and B7-H4 35, which are associated with differentiation and recruitment of Tregs. Moreover, the hypoxia milieu in ovarian tumors can promote the recruitment of Tregs by inducing the expression of CCL28, thereby advancing angiogenesis and tumor tolerance 46.

Tregs suppress tumor specific-T cells responses and contribute to tumor progression by secreting soluble or membranous immunosuppressive mediators, suppressing DCs, and disrupting metabolic and cytolytic activity. TGF-β and IL-10 47 derived from Tregs are shown to be the key cytokines that block T cell proliferation, limit antitumor immunity and promote tumor progression. As previously alluded to, ovarian cancer patients present with high levels of TNF. TNF receptor 2 (TNFR2)-expressing Tregs are found to be abundantly infiltrated in tumor-associated ascites. This subpopulation of Tregs are maximally suppressive and show increased suppressive activity compared to peripheral blood TNFR2+ Tregs in patients 48. CTLA-4 was also highly expressed on the Tregs, binds to partner members on APC and transmits an inhibitory signal to TILs 49. The prevailing view about Tregs in ovarian cancer is that they suppress the antitumor immunity. However, lately, an evaluation of 73 ovarian cancer patients found that Tregs show a positive prognostic factor 50. What accounts for these differences is unknown.

Tumor-associated dendritic cells (tDCs)

The mature DCs are required for initiating and sustaining T cell-dependent antitumor immunity. However, ovarian cancers can subvert the normal activity of DCs, switching their role from immunostimulatory to immunosuppressive, to inhibit the function of antitumor T cells. A number of factors existing in the ovarian TME implemented by the tumor or nontumor cells contribute to this transition, which can disrupt normal DC functions, including various soluble factors such as TGF-β, IL-10, VEGF, arginase I and expression of surface molecules such as IDO, PD-L1, and PD-1. The large amounts of IL-10 accumulated in ovarian cancers promote differentiation of DCs into CD14+CD1a- macrophage-like cells, which are ineffective in inducing the T cell response 51. CXCR4+ plasmacytoid precursor cells, the precursors of plasmacytoid DCs, are recruited into the ovarian cancer milieu by tumor-derived CXCL-12, inducing secretion of IL-10 and further preventing T cell activation 52. Additionally, plasmacytoid DCs accumulated in ascites of ovarian cancer patients induce angiogenesis by the production of TGF-β and IL-8 53. VEGF, which is markedly elevated in the ascites of ovarian cancer patients, prevented maturation of DCs in patients, impaired the generation of antitumor immunity, and is correlated with a poor prognosis of ovarian cancers 54. The level of arginase I in serum of ovarian cancer patients increasing can promote TILs anergy by depleting L-arginine 55. PD-L1 is highly expressed on the surface of myeloid-derived DCs in ovarian cancer, which has been shown to inhibit the proliferation of T cells directly and promote the infiltration of Tregs indirectly 56. PD-1, the ligand of PD-L1, is upregulated on TILs in ovarian cancer and, notably, was involved in paralyzing the activation of T cells 57. Not only PD-L1/PD-1 but also myeloid-derived DCs mediate immune suppression by inducing IDO, reactive oxygen species, etc 58. SATB1 is necessary for DCs to mature, while the time window required by SATB1 is very narrow. Once DCs mature, SATB1 disappears. However, SATB1 persists in ovarian cancer-associated DCs and induces secretion of immunosuppressive molecules. Silencing SATB1 by delivering miR-155 to DCs can reverse this condition 59. The latest research demonstrated that abnormal lipid accumulation in tDCs, which is caused by constitutive activation of XBP1, inhibits the capacity of tDCs and subsequently the progression of antitumor immunity. DC-specific deletion of XBP1 can convert immunosuppression into immunostimulation 60.

Myeloid-derived suppressor cells (MDSCs)

MDSCs, a heterogeneous population of immature myeloid cells, inhibit T-cell responses and secrete factors that promote tumor growth, invasion, and metastasis. MDSCs infiltrate in the local TME and systemically serve as a function of disease burden in ovarian cancer. In ovarian cancer, the recruitment of MDSCs toward ascites occurs in a CXCR4-dependent manner, which requires cyclooxygenase-2 (COX2), the key enzyme in prostaglandin E2 (PGE2) synthesis. PGE2 is essential for both production of CXCL12 and expression of CXCR4 in MDSCs 61. Moreover, PGE2 and COX2 redirect the development of CD1a+ DCs to CD14+CD33+CD34+ monocytic MDSCs and induce the expression of MDSC-associated immunosuppressive factors, IDO, arginase 1, NOS2, IL-10 and COX2, thereby inhibiting the cytotoxic T lymphocyte response 62. A recent study found that COX2, synergized by IFN-γ and TNF-α, hyperactivates the MDSCs within the ovarian cancer microenvironment, causing overexpression of MDSC-associated immunosuppressive factors, which leads to strong feedback suppression in type-1 immune response 63. That is, COX2-PGE2 feedback is critical in the induction and persistence of MDSCs. The inhibition of COX2-PGE2 feedback in MDSCs blocks the accumulation of MDSCs and restores the antitumor response. Additionally, MDSCs enhance stemness of ovarian cancer cells by inducing miRNA101 expression and subsequently repressing the co-repressor gene C-terminal binding protein-2 (CtBP2). CtBP2 increases cancer cell stemness and promotes metastatic and tumorigenic potential by directly targeting stem cell core genes 64. MDSCs are an important immune component and are thought to mediate immune suppression in the ovarian tumor microenvironment, while they are still poorly defined.

Tumor-infiltrating lymphocytes (TILs)

TILs are a lymphocyte-based heterogeneous population located in tumor stroma or intreapthelium. Generally, CD3+ cells are predominant in TILs, and the proportions of CD4+ and CD8+ cells vary in different cancers. It has been confirmed that TILs are the vigorous power that exerts significant pressure against many kinds of cancer, including ovarian cancer.

TIL infiltration in ovarian cancer were found as early as 1982 65, but it was not until 2003 that the positive prognostic for increased overall survival of these cells in ovarian cancer was determined 66. In that publication, the researchers found that the ovarian cancer patients with CD3+ TIL infiltration in the tumor had significantly increased long-term survival compared to those patients with no TILs. This gap in the 5-year survival rate between with or without TILs stubbornly persists after complete clinical therapy 66. The survival benefit of CD3+ cells in ovarian cancer has also been echoed by several other studies. However, more studies chorused their approval of CD8+ T cells as the positive prognostic index in ovarian cancer. A study of 117 ovarian cancer specimens observed that intraepithelial CD8+ T cell infiltration in the tumor is associated with a good outcome 67, and these conclusions were confirmed by other teams. CD4+ TILs have been associated with positive prognosis as well 68; however, because CD4+ TILs function as a marker together with Tregs, the role of CD4+ TILs are indefinite. One study demonstrated that epithelial ovarian cancer patients with high intraepithelial CD8+ /CD4+ ratios compared to those with a low ratio show better prognosis in terms of survival, suggesting an inhibitory role for Tregs 67. Th17 cells, a subset of CD4+ T cells, were negatively associated with infiltration of Tregs and correlated with prolonged overall survival in ovarian cancer. Recently, TILs with a specific marker, CD103, were found to abundantly infiltrate in ovarian cancer and were distinctly associated with increased survival rates 69. CD103+ TILs isolated from high-grade epithelial ovarian cancer were confirmed localized in the cancer epithelium predominantly 70.

Due to the heterogeneity of TILs, there are many different ideas about which subset of TILs actually play the pivotal role in the anti-tumor response. Some cohorts support that CD8+ T cells demonstrated improved survival over CD3+ cells 67, while several other groups indicate that both CD8+ and CD3+ TILs are responsible for positive prognoses in ovarian cancer 71. A few studies even concluded that there is no relationship between TILs and survival 72. Although there are a few opposing opinions, it is widely accepted that TILs, especially CD8+ TILs, serve as a positive factor in ovarian cancer.

By limiting the homing, infiltration and function of TILs, tumors exploit multiple obstacles to hinder the anti-tumor immune response, particularly for patients without preexisting TILs. Enhanced angiogenesis in ovarian cancer results in a substantial barrier to the infiltration of tumor-specific T cells, which is associated with the absence of TILs in patients. In ovarian cancer, overexpressed VEGF enhances the proliferation, migration and invasion of endothelial cells and correlates with increased microvascular density 73. VEGF-A can also attenuate the adhesive interaction between lymphocytes and tumor vascular endothelial cells and then decrease TIL penetration through deregulation of ICAM-1 and vascular cell adhesion molecule-1 (VCAM-1) 74. Moreover, in collaboration with IL-10 and PGE2, VEGF-A can induce FasL expression in endothelial cells, and the higher expression of FasL is associated with allowing more Tregs than CD8+ T cells to traffic selectively 75. Furthermore, VEGF has also been shown to inhibit CD8+ T cells by recruiting MDSCs, and the VEGF-induced MDSCs were more strongly immunosuppressive. In mouse ovarian cancer models, anti-VEGF treatments decreased tumor growth and ascites production effectively 76. Increasing evidence showed that VEGF is a promising therapeutic target, especially for malignant ascites. In addition, the ETBR pathway restricts endothelial-T cell adhesion and blocks the entry of T cells 77. Blockade of VEGF-A or ETBR increases TIL infiltration in tumors. Angiogenesis is also enhanced by IL-6. Functional IL-6R has been found in endothelial cells in both normal ovaries and ovarian cancers, and IL-6-IL6R may trigger angiogenesis. In addition, IL-6 can upregulate the expression of VEGF 78. Immature myeloid-derived DCs have been reported to promote vasculogenesis and angiogenesis 79. Apart from the endothelial barrier, expression levels of SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily E member 1(SMARCE1) and thyroid transcription factor-1 (TTF1) mRNA in SKOV3 are reported to be distinctly correlated with CD8+ T cell infiltration by inducing secretion of different chemokines, including IL-8 80.

Upon arrival within the TME, TILs will face a difficult dilemma in the local immunosuppressive surroundings constructed by tumor cells and immunosuppressive cells, such as Tregs, TAMs, and MDSCs. In addition to interfering with TILs homing, the tumor endothelium also restrains the normal function of TILs. Several molecules, such as PD-L1, B7-H3, IDO, arginase-I, IL-10, TGF-β, PGE2, that are expressed or produced by endothelial cells can suppress or kill effector TILs. B7-H3, like B7-H4, is a co-inhibitory member in the B7-CD28 family, which protect T cells from excessive activation under physiological conditions and attenuate natural anti-tumor immunity. B7-H3 is overexpressed in ovarian cancer specimens at the protein level and predicts poor survival 81. The mechanism of B7-H3 in immunosuppression is not clear, mainly because its receptor is not definite. The PD-L1/PD-1 pathway promotes TIL apoptosis and energy 56. Overexpression of PD-L1 on ID8 cells, a mouse ovarian cancer cell line, inhibits CTL degranulation and decreases CTL-mediated tumor lysis 82. In human ovarian cancer, PD-L1 expressed on monocyte higher than those patients with borderline disease, and there is a significant negative correlation between intraepithelial CD8+ cells and PD-1 on tumor cells. Whereas, several studies published recently declared that high PD-1 and PD-L1 levels are demonstrated as favorable prognosis indicators for progression-free and overall survival of ovarian cancer. Reasons for these discordant results is still unknown, maybe more complex immune regulation mechanisms are involved. A recent study concluded that the PD-L1/PD-1 pathway in blood could be used as a prognostic marker for potential diagnosis of epithelial ovarian cancer 83. IDO and arginase-I have been found to disturb metabolism of TILs. IDO is prevalent in approximately 56% of ovarian tumors. By consuming tryptophan and forming kynurenine, IDO promotes tumor angiogenesis and suppresses the proliferation and function of TILs, thus playing an important role in tumor invasion 84. Increased levels of TGF-β in ovarian cancer milieu are vital not only for inducing Tregs but also for heightening angiogenesis directly 85, suppressing the proliferation and activation of TILs, and enhancing invasion of ovarian cancer cells. A study of the invasion of ovarian cancer cell lines found that TGF-β enhances the invasiveness of ovarian cancer cell lines by partially inducing the activation of MMP 86. In addition, tumor cells dampened the function of TILs by imposing a glucose restriction on them and constrained the expression of methyltransferase EZH2 by highly expressing the microRNAs miR-101 and miR-26a, which are involved in this progress 87.

The role of IL-17 in ovarian cancer is still ambiguous. One study identified that cross talk between γδ T lymphocytes and small peritoneal macrophages (SPMs) mediated by IL-17 promotes ovarian cancer growth 88. However, a meta-analysis revealed that IL-17 predicted better overall survival and disease-free survival in ovarian cancer patients 89. Similarly, IL-17 was reported to synergize with IFN-γ, co-expressed by Th17 cells and induce more Th1-type chemokines CXCL9/10, which correlated with the reduction in angiogenesis and progression of a tumor 90. Concerning the unclear manifestation of IL-17 in tumor growth and progression, some researchers assumed that the definite function of IL-17 might depend on the immunogenicity of a tumor, the immune status of the patient, and the phase of the disease. In addition, the origin and histopathological classification of tumors should also be taken into consideration 89.

Conclusions

Ovarian cancer is an immunogenic tumor and immunotherapy offers a novel and promising therapeutic strategy for treating it. Even though immunotherapy is developing rapidly and has yielded impressive breakthroughs, many patients with ovarian cancer still fail to respond to this treatment. This is quite possibly due to the highly complex immunosuppressive network. The cunning tumor cells inveigle self-serving forces and suppress dissent to found an indestructible “fortress” where the tumor is invincible and can grow unhampered. In this condition, TILs always fight alone without any support and have to succumb to the tumor cells finally. Therefore, a better understanding of the immune microenvironment in ovarian cancer can help the researchers find some effective breakthrough points to extend the clinical success of cancer immunotherapy. So, we highlighted on the establishment of immune tolerance by how ovarian cancer cells recruit and re-educate immunosuppressive components and how this immunosuppressive network prevents TILs from anti-tumor response. In this succession of immune-suppressive components in ovarian cancer microenvironment, the researches on TAMs are relatively extensive. This may be due to its characteristics. TAMs account for a large proportion of immune cells infiltrated in ovarian cancer, and show immunosuppressive phenotype after the re-education of the ovarian cancer cells. Not only circulating monocytes, tissue-resident macrophages also have been confirmed as a substantial source for the TAMs that there is a surprising similarity between peritoneal macrophages and TAMs. In TME, the factors participant in polarizing TAMs are varied and complex. In addition to some immunosuppressive chemokines and cytokines, the role of tumor-derived exosomes, metabolites even genes in the accumulation of TAMs has been concerned and published recently. The specific contents are described in detail in the text. It is easy to see from the structure and length of the article that the researches about Tregs, tDCs as well as MDSC are few. The immune network is a whole and a more thorough study about these cells will help to better understand the ovarian cancer immunity.

Acknowledgments

This work was supported by the National Natural Science Foundation of China (NSFC) (No. 81671460) to Li-Ping Jin.

Abbreviations

AhR
Aryl hydrocarbon receptor
COX2
Cyclooxygenase-2
CSF-1
Colony stimulating factor 1
CtBP2
C-terminal binding protein-2
EGF
endothelial growth factor
EMMPRIN
Extracellular matrix metalloproteinase inducer
HMGB1
high-mobility group box protein 1
HPMCs
Human peritoneal mesothelial cells
ICAM-1
Intercellular cell adhesion molecule-1
IDO
Indoleamine 2,3-dioxygenase
LIF
leukemia inhibitory factor
MCP-1
monocyte chemotactic protein MDSCs: Myeloid-derived suppressor cells
MIF
Macrophage migration inhibitory factor
MMP
Matrix metalloproteinase
MR
mannose receptor
PGE2
Prostaglandin E2
SDF-1
Stroma-derived factor 1
SMARCE1
SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily E member 1;SPMs: Small peritoneal macrophages
SR-A
Scavenger receptor-A
TAMs
Tumor-associated macrophages
tDCs
Tumor-associated dendritic cells
TILs
Tumor-infiltrating lymphocytes
TME
tumor microenvironment
Tregs
T-regulatory cells
TTF1
Tyroid transcription factor-1
VCAM-1
Vascular cell adhesion molecule-1
5-LOX
5-lipoxygenase.

References

1. Colvin EK. Tumor-associated macrophages contribute to tumor progression in ovarian cancer. Front Oncol. 2014;4:137. [PMC free article] [PubMed]
2. Mantovani A, Sozzani S, Locati M. et al. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002;23:549–55. [PubMed]
3. Reinartz S, Schumann T, Finkernagel F. et al. Mixed-polarization phenotype of ascites-associated macrophages in human ovarian carcinoma: correlation of CD163 expression, cytokine levels and early relapse. Int J Cancer. 2014;134:32–42. [PMC free article] [PubMed]
4. Negus RP, Stamp GW, Relf MG. et al. The detection and localization of monocyte chemoattractant protein-1 (MCP-1) in human ovarian cancer. J Clin Invest. 1995;95:2391–6. [PMC free article] [PubMed]
5. Sica A, Saccani A, Bottazzi B. et al. Defective expression of the monocyte chemotactic protein-1 receptor CCR2 in macrophages associated with human ovarian carcinoma. J Immunol. 2000;164:733–8. [PubMed]
6. Wynn TA, Chawla A, Pollard JW. Macrophage biology in development, homeostasis and disease. Nature. 2013;496:445–55. [PMC free article] [PubMed]
7. Finkernagel F, Reinartz S, Lieber S. et al. The transcriptional signature of human ovarian carcinoma macrophages is associated with extracellular matrix reorganization. Oncotarget. 2016;7:75339–52. [PMC free article] [PubMed]
8. Chambers SK, Kacinski BM, Ivins CM. et al. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1. Clin Cancer Res. 1997;3:999–1007. [PubMed]
9. Moughon DL, He H, Schokrpur S. et al. Macrophage Blockade Using CSF1R Inhibitors Reverses the Vascular Leakage Underlying Malignant Ascites in Late-Stage Epithelial Ovarian Cancer. Cancer Res. 2015;75:4742–52. [PMC free article] [PubMed]
10. Duluc D, Delneste Y, Tan F. et al. Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cells. Blood. 2007;110:4319–30. [PubMed]
11. Hagemann T, Wilson J, Burke F. et al. Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype. J Immunol. 2006;176:5023–32. [PubMed]
12. Allavena P, Chieppa M, Bianchi G. et al. Engagement of the mannose receptor by tumoral mucins activates an immune suppressive phenotype in human tumor-associated macrophages. Clin Dev Immunol. 2010;2010:547179. [PMC free article] [PubMed]
13. He YF, Zhang MY, Wu X. et al. High MUC2 expression in ovarian cancer is inversely associated with the M1/M2 ratio of tumor-associated macrophages and patient survival time. PLoS One. 2013;8:e79769. [PMC free article] [PubMed]
14. Ying X, Wu Q, Wu X. et al. Epithelial ovarian cancer-secreted exosomal miR-222-3p induces polarization of tumor-associated macrophages. Oncotarget. 2016;7:43076–87. [PMC free article] [PubMed]
15. Wen Z, Liu H, Li M. et al. Increased metabolites of 5-lipoxygenase from hypoxic ovarian cancer cells promote tumor-associated macrophage infiltration. Oncogene. 2015;34:1241–52. [PubMed]
16. Ko SY, Ladanyi A, Lengyel E. et al. Expression of the homeobox gene HOXA9 in ovarian cancer induces peritoneal macrophages to acquire an M2 tumor-promoting phenotype. Am J Pathol. 2014;184:271–81. [PubMed]
17. Gordon IO, Freedman RS. Defective antitumor function of monocyte-derived macrophages from epithelial ovarian cancer patients. Clin Cancer Res. 2006;12:1515–24. [PubMed]
18. Lan C, Huang X, Lin S. et al. Expression of M2-polarized macrophages is associated with poor prognosis for advanced epithelial ovarian cancer. Technol Cancer Res Treat. 2013;12:259–67. [PubMed]
19. Robinson-Smith TM, Isaacsohn I, Mercer CA. et al. Macrophages mediate inflammation-enhanced metastasis of ovarian tumors in mice. Cancer Res. 2007;67:5708–16. [PubMed]
20. Hagemann T, Wilson J, Kulbe H. et al. Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK. J Immunol. 2005;175:1197–205. [PubMed]
21. Hagemann T, Robinson SC, Thompson RG. et al. Ovarian cancer cell-derived migration inhibitory factor enhances tumor growth, progression, and angiogenesis. Mol Cancer Ther. 2007;6:1993–2002. [PubMed]
22. Curiel TJ, Coukos G, Zou L. et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10:942–9. [PubMed]
23. Lane D, Matte I, Laplante C. et al. CCL18 from ascites promotes ovarian cancer cell migration through proline-rich tyrosine kinase 2 signaling. Mol Cancer. 2016;15:58. [PMC free article] [PubMed]
24. Wang Q, Tang Y, Yu H. et al. CCL18 from tumor-cells promotes epithelial ovarian cancer metastasis via mTOR signaling pathway. Mol Carcinog. 2016;55:1688–99. [PMC free article] [PubMed]
25. Duluc D, Corvaisier M, Blanchard S. et al. Interferon-gamma reverses the immunosuppressive and protumoral properties and prevents the generation of human tumor-associated macrophages. Int J Cancer. 2009;125:367–73. [PubMed]
26. Yin M, Li X, Tan S. et al. Tumor-associated macrophages drive spheroid formation during early transcoelomic metastasis of ovarian cancer. J Clin Invest. 2016;126:4157–73. [PMC free article] [PubMed]
27. Neyen C, Pluddemann A, Mukhopadhyay S. et al. Macrophage scavenger receptor a promotes tumor progression in murine models of ovarian and pancreatic cancer. J Immunol. 2013;190:3798–805. [PMC free article] [PubMed]
28. Hagemann T, Lawrence T, McNeish I. et al. "Re-educating" tumor-associated macrophages by targeting NF-kappaB. J Exp Med. 2008;205:1261–8. [PMC free article] [PubMed]
29. Piura B, Medina L, Rabinovich A. et al. Distinct expression and localization of TNF system in ovarian carcinoma tissues: possible involvement of TNF-alpha in morphological changes of ovarian cancerous cells. Anticancer Res. 2014;34:745–52. [PubMed]
30. Kulbe H, Chakravarty P, Leinster DA. et al. A dynamic inflammatory cytokine network in the human ovarian cancer microenvironment. Cancer Res. 2012;72:66–75. [PMC free article] [PubMed]
31. Bax HJ, Josephs DH, Pellizzari G. et al. Therapeutic targets and new directions for antibodies developed for ovarian cancer. MAbs. 2016;8:1437–55. [PMC free article] [PubMed]
32. Righi E, Kashiwagi S, Yuan J. et al. CXCL12/CXCR4 blockade induces multimodal antitumor effects that prolong survival in an immunocompetent mouse model of ovarian cancer. Cancer Res. 2011;71:5522–34. [PMC free article] [PubMed]
33. Kajiyama H, Shibata K, Terauchi M. et al. Involvement of SDF-1alpha/CXCR4 axis in the enhanced peritoneal metastasis of epithelial ovarian carcinoma. Int J Cancer. 2008;122:91–9. [PubMed]
34. Kryczek I, Zou L, Rodriguez P. et al. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med. 2006;203:871–81. [PMC free article] [PubMed]
35. Kryczek I, Wei S, Zhu G. et al. Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma. Cancer Res. 2007;67:8900–5. [PubMed]
36. Wang X, Zhao X, Wang K. et al. Interaction of monocytes/macrophages with ovarian cancer cells promotes angiogenesis in vitro. Cancer Sci. 2013;104:516–23. [PubMed]
37. Zhang W, Tian J, Hao Q. HMGB1 combining with tumor-associated macrophages enhanced lymphangiogenesis in human epithelial ovarian cancer. Tumour Biol. 2014;35:2175–86. [PubMed]
38. Wolf D, Wolf AM, Rumpold H. et al. The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res. 2005;11:8326–31. [PubMed]
39. Tan MC, Goedegebuure PS, Belt BA. et al. Disruption of CCR5-dependent homing of regulatory T cells inhibits tumor growth in a murine model of pancreatic cancer. J Immunol. 2009;182:1746–55. [PMC free article] [PubMed]
40. Fialova A, Partlova S, Sojka L. et al. Dynamics of T-cell infiltration during the course of ovarian cancer: the gradual shift from a Th17 effector cell response to a predominant infiltration by regulatory T-cells. Int J Cancer. 2013;132:1070–9. [PubMed]
41. Jonuleit H, Schmitt E, Schuler G. et al. Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med. 2000;192:1213–22. [PMC free article] [PubMed]
42. Ghiringhelli F, Puig PE, Roux S. et al. Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J Exp Med. 2005;202:919–29. [PMC free article] [PubMed]
43. Chen W, Jin W, Hardegen N. et al. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med. 2003;198:1875–86. [PMC free article] [PubMed]
44. Wei S, Kryczek I, Zou L. et al. Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma. Cancer Res. 2005;65:5020–6. [PubMed]
45. Wang L, Pino-Lagos K, de Vries VC. et al. Programmed death 1 ligand signaling regulates the generation of adaptive Foxp3+CD4+ regulatory T cells. Proc Natl Acad Sci U S A. 2008;105:9331–6. [PubMed]
46. Facciabene A, Peng X, Hagemann IS. et al. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature. 2011;475:226–30. [PubMed]
47. Strauss L, Bergmann C, Szczepanski M. et al. A unique subset of CD4+CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment. Clin Cancer Res. 2007;13:4345–54. [PubMed]
48. Govindaraj C, Scalzo-Inguanti K, Madondo M. et al. Impaired Th1 immunity in ovarian cancer patients is mediated by TNFR2+ Tregs within the tumor microenvironment. Clin Immunol. 2013;149:97–110. [PubMed]
49. Takahashi T, Tagami T, Yamazaki S. et al. Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med. 2000;192:303–10. [PMC free article] [PubMed]
50. Mhawech-Fauceglia P, Wang D, Ali L. et al. Intraepithelial T cells and tumor-associated macrophages in ovarian cancer patients. Cancer Immun. 2013;13:1. [PMC free article] [PubMed]
51. Chen F, Hou M, Ye F. et al. Ovarian cancer cells induce peripheral mature dendritic cells to differentiate into macrophagelike cells in vitro. Int J Gynecol Cancer. 2009;19:1487–93. [PubMed]
52. Zou W, Machelon V, Coulomb-L'Hermin A. et al. Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat Med. 2001;7:1339–46. [PubMed]
53. Curiel TJ, Cheng P, Mottram P. et al. Dendritic cell subsets differentially regulate angiogenesis in human ovarian cancer. Cancer Res. 2004;64:5535–8. [PubMed]
54. Hazelton D, Nicosia RF, Nicosia SV. Vascular endothelial growth factor levels in ovarian cyst fluid correlate with malignancy. Clin Cancer Res. 1999;5:823–9. [PubMed]
55. Iakubets OI, Fafula RV, Vorobets DZ. et al. [Arginase and NO-synthase pathways of L-arginine metabolism in peripheral blood lymphocytes of patients with ovarian cancer] Ukr Biokhim Zh (1999) 2013;85:105–13. [PubMed]
56. Curiel TJ, Wei S, Dong H. et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med. 2003;9:562–7. [PubMed]
57. Matsuzaki J, Gnjatic S, Mhawech-Fauceglia P. et al. Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci U S A. 2010;107:7875–80. [PubMed]
58. Preston CC, Goode EL, Hartmann LC. et al. Immunity and immune suppression in human ovarian cancer. Immunotherapy. 2011;3:539–56. [PMC free article] [PubMed]
59. Poh A. How Ovarian Cancer Evades Immune Scrutiny. Cancer Discov. 2016;6:OF1. [PubMed]
60. Cubillos-Ruiz JR, Silberman PC, Rutkowski MR. et al. ER Stress Sensor XBP1 Controls Anti-tumor Immunity by Disrupting Dendritic Cell Homeostasis. Cell. 2015;161:1527–38. [PMC free article] [PubMed]
61. Obermajer N, Muthuswamy R, Odunsi K. et al. PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment. Cancer Res. 2011;71:7463–70. [PMC free article] [PubMed]
62. Obermajer N, Muthuswamy R, Lesnock J. et al. Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells. Blood. 2011;118:5498–505. [PubMed]
63. Wong JL, Obermajer N, Odunsi K. et al. Synergistic COX2 Induction by IFNgamma and TNFalpha Self-Limits Type-1 Immunity in the Human Tumor Microenvironment. Cancer Immunol Res. 2016;4:303–11. [PMC free article] [PubMed]
64. Cui TX, Kryczek I, Zhao L. et al. Myeloid-derived suppressor cells enhance stemness of cancer cells by inducing microRNA101 and suppressing the corepressor CtBP2. Immunity. 2013;39:611–21. [PMC free article] [PubMed]
65. Haskill S, Becker S, Fowler W. et al. Mononuclear-cell infiltration in ovarian cancer. I. Inflammatory-cell infiltrates from tumour and ascites material. Br J Cancer. 1982;45:728–36. [PMC free article] [PubMed]
66. Zhang L, Conejo-Garcia JR, Katsaros D. et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003;348:203–13. [PubMed]
67. Sato E, Olson SH, Ahn J. et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A. 2005;102:18538–43. [PubMed]
68. Hamanishi J, Mandai M, Abiko K. et al. The comprehensive assessment of local immune status of ovarian cancer by the clustering of multiple immune factors. Clin Immunol. 2011;141:338–47. [PubMed]
69. Bosmuller HC, Wagner P, Peper JK. et al. Combined Immunoscore of CD103 and CD3 Identifies Long-Term Survivors in High-Grade Serous Ovarian Cancer. Int J Gynecol Cancer. 2016;26:671–9. [PubMed]
70. Komdeur FL, Wouters MC, Workel HH. et al. CD103+ intraepithelial T cells in high-grade serous ovarian cancer are phenotypically diverse TCRalphabeta+ CD8alphabeta+ T cells that can be targeted for cancer immunotherapy. Oncotarget. 2016;7:75130–44. [PMC free article] [PubMed]
71. Clarke B, Tinker AV, Lee CH. et al. Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss. Mod Pathol. 2009;22:393–402. [PubMed]
72. Al-Attar A, Shehata M, Durrant L. et al. T cell density and location can influence the prognosis of ovarian cancer. Pathol Oncol Res. 2010;16:361–70. [PubMed]
73. Kassim SK, El-Salahy EM, Fayed ST. et al. Vascular endothelial growth factor and interleukin-8 are associated with poor prognosis in epithelial ovarian cancer patients. Clin Biochem. 2004;37:363–9. [PubMed]
74. Bouzin C, Brouet A, De Vriese J. et al. Effects of vascular endothelial growth factor on the lymphocyte-endothelium interactions: identification of caveolin-1 and nitric oxide as control points of endothelial cell anergy. J Immunol. 2007;178:1505–11. [PubMed]
75. Motz GT, Santoro SP, Wang LP. et al. Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat Med. 2014;20:607–15. [PMC free article] [PubMed]
76. Horikawa N, Abiko K, Matsumura N. et al. Expression of Vascular Endothelial Growth Factor in Ovarian Cancer Inhibits Tumor Immunity through the Accumulation of Myeloid-Derived Suppressor Cells. Clin Cancer Res. 2017;23:587–99. [PubMed]
77. Buckanovich RJ, Facciabene A, Kim S. et al. Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nat Med. 2008;14:28–36. [PubMed]
78. Nilsson MB, Langley RR, Fidler IJ. Interleukin-6, secreted by human ovarian carcinoma cells, is a potent proangiogenic cytokine. Cancer Res. 2005;65:10794–800. [PMC free article] [PubMed]
79. Schmid MC, Varner JA. Myeloid cells in the tumor microenvironment: modulation of tumor angiogenesis and tumor inflammation. J Oncol. 2010;2010:201026. [PMC free article] [PubMed]
80. Giannakakis A, Karapetsas A, Dangaj D. et al. Overexpression of SMARCE1 is associated with CD8+ T-cell infiltration in early stage ovarian cancer. Int J Biochem Cell Biol. 2014;53:389–98. [PubMed]
81. Fauci JM, Straughn JM Jr. et al. A review of B7-H3 and B7-H4 immune molecules and their role in ovarian cancer. Gynecol Oncol. 2012;127:420–5. [PubMed]
82. Chester C, Dorigo O, Berek JS. et al. Immunotherapeutic approaches to ovarian cancer treatment. J Immunother Cancer. 2015;3:7. [PMC free article] [PubMed]
83. Chatterjee J, Dai W, Aziz NHA, Clinical Use of Programmed Cell Death-1 and Its Ligand Expression as Discriminatory and Predictive Markers in Ovarian Cancer. Clin Cancer Res; 2016. [PubMed]
84. Inaba T, Ino K, Kajiyama H. et al. Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinoma. Gynecol Oncol. 2009;115:185–92. [PubMed]
85. Pepper MS. Transforming growth factor-beta: vasculogenesis, angiogenesis, and vessel wall integrity. Cytokine Growth Factor Rev. 1997;8:21–43. [PubMed]
86. Rodriguez GC, Haisley C, Hurteau J. et al. Regulation of invasion of epithelial ovarian cancer by transforming growth factor-beta. Gynecol Oncol. 2001;80:245–53. [PubMed]
87. Zhao E, Maj T, Kryczek I. et al. Cancer mediates effector T cell dysfunction by targeting microRNAs and EZH2 via glycolysis restriction. Nat Immunol. 2016;17:95–103. [PMC free article] [PubMed]
88. Rei M, Goncalves-Sousa N, Lanca T. et al. Murine CD27(-) Vgamma6(+) gammadelta T cells producing IL-17A promote ovarian cancer growth via mobilization of protumor small peritoneal macrophages. Proc Natl Acad Sci U S A. 2014;111:E3562–70. [PubMed]
89. Zeng Y, Zhang Q, Wang H. et al. Prognostic significance of interleukin-17 in solid tumors: a meta-analysis. Int J Clin Exp Med. 2015;8:10515–36. [PMC free article] [PubMed]
90. Kryczek I, Banerjee M, Cheng P. et al. Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood. 2009;114:1141–9. [PubMed]

Articles from Journal of Cancer are provided here courtesy of Ivyspring International Publisher